The compound you described, **1-(3-amino-7-methoxy-1-pyrazolo[3,4-b]quinolinyl)-2-(4-chlorophenyl)ethanone**, is a complex organic molecule with potential biological activity. Here's a breakdown:
**Structure and Properties:**
* **Pyrazolo[3,4-b]quinoline:** This core structure is a fused ring system containing both a pyrazole and a quinoline ring.
* **Substituents:** The molecule has various substituents attached to this core structure:
* **3-amino:** An amino group (-NH2) at the 3rd position of the pyrazole ring.
* **7-methoxy:** A methoxy group (-OCH3) at the 7th position of the quinoline ring.
* **1-(4-chlorophenyl)ethanone:** A 4-chlorophenyl ketone group attached to the 1st position of the pyrazole ring.
**Potential Importance for Research:**
This compound is likely of interest for research due to its structural similarity to known bioactive molecules. Here's why:
* **Pyrazoloquinoline Analogues:** Pyrazolo[3,4-b]quinolines are a class of compounds with diverse pharmacological activities. Some examples include:
* **Anti-cancer agents:** Several pyrazoloquinolines have shown promising activity against various cancer cell lines.
* **Anti-inflammatory agents:** Some compounds in this class have been investigated for their anti-inflammatory potential.
* **Anti-microbial agents:** Pyrazoloquinolines have also been studied for their antimicrobial properties.
* **Chlorophenyl Ketone Group:** This group is commonly found in pharmaceuticals and can influence the molecule's ability to interact with biological targets.
**Further Research:**
Without more information, it's impossible to say exactly why this specific compound is being studied. However, its structure suggests potential for research in areas such as:
* **Drug discovery:** Investigating this compound's biological activity could lead to the development of new therapeutic agents.
* **Medicinal chemistry:** Studying the molecule's interactions with biological targets can help researchers understand the structure-activity relationships of this class of compounds.
* **Synthesis and characterization:** Developing efficient methods to synthesize and purify this compound is crucial for further research.
**Key Points:**
* This compound is likely being studied for its potential biological activity, particularly in areas related to medicine and drug discovery.
* Its structural similarity to known bioactive molecules makes it a promising candidate for further investigation.
* Additional research is needed to fully understand its properties and potential applications.
ID Source | ID |
---|---|
PubMed CID | 6619057 |
CHEMBL ID | 1303886 |
CHEBI ID | 115715 |
Synonym |
---|
MLS000522343 , |
smr000127611 |
IDI1_004256 |
CHEMDIV2_005541 |
CHEBI:115715 |
HMS1384L19 |
AKOS001763975 |
1-(3-amino-7-methoxy-1h-pyrazolo[3,4-b]quinolin-1-yl)-2-(4-chlorophenyl)-1-ethanone |
1-(3-amino-7-methoxypyrazolo[3,4-b]quinolin-1-yl)-2-(4-chlorophenyl)ethanone |
CHEMBL1303886 |
HMS2257I03 |
1-(3-amino-7-methoxy-1-pyrazolo[3,4-b]quinolinyl)-2-(4-chlorophenyl)ethanone |
1-(3-amino-7-methoxy-pyrazolo[3,4-b]quinolin-1-yl)-2-(4-chlorophenyl)ethanone |
1-(3-azanyl-7-methoxy-pyrazolo[3,4-b]quinolin-1-yl)-2-(4-chlorophenyl)ethanone |
cid_6619057 |
bdbm40184 |
HMS3433K10 |
Q27198066 |
SR-01000119236-1 |
sr-01000119236 |
Class | Description |
---|---|
quinolines | A class of aromatic heterocyclic compounds each of which contains a benzene ring ortho fused to carbons 2 and 3 of a pyridine ring. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 39.8107 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
Chain A, Cruzipain | Trypanosoma cruzi | Potency | 31.6228 | 0.0020 | 14.6779 | 39.8107 | AID1476 |
thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 0.1000 | 0.1000 | 20.8793 | 79.4328 | AID588453 |
phosphopantetheinyl transferase | Bacillus subtilis | Potency | 39.8107 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 3.6626 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
67.9K protein | Vaccinia virus | Potency | 2.5119 | 0.0001 | 8.4406 | 100.0000 | AID720579 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 100.0000 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
huntingtin isoform 2 | Homo sapiens (human) | Potency | 7.9433 | 0.0006 | 18.4198 | 1,122.0200 | AID1688 |
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 89.1251 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 17.7828 | 0.0079 | 8.2332 | 1,122.0200 | AID2551 |
geminin | Homo sapiens (human) | Potency | 20.5962 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 14.1254 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 11.2202 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Estrogen receptor 1 | Homo sapiens (human) | IC50 (µMol) | 24.7833 | 2.1616 | 13.6892 | 26.3472 | AID713 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
negative regulation of inflammatory response to antigenic stimulus | Guanine nucleotide-binding protein G | Homo sapiens (human) |
renal water homeostasis | Guanine nucleotide-binding protein G | Homo sapiens (human) |
G protein-coupled receptor signaling pathway | Guanine nucleotide-binding protein G | Homo sapiens (human) |
regulation of insulin secretion | Guanine nucleotide-binding protein G | Homo sapiens (human) |
cellular response to glucagon stimulus | Guanine nucleotide-binding protein G | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
G protein activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
adenylate cyclase activator activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
plasma membrane | Guanine nucleotide-binding protein G | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |